ASX 200 Holds Uptrend Despite Resistance

• ASX 200: The setup remains bullish, but the index is testing resistance near current highs.
• Telstra: Momentum is waning after a strong run.
• Rio Tinto: The stock is locked in a range and waiting for direction.
• Sigma Healthcare: The share price is holding steady after a 129% yearly surge

During Monday’s trading session, the ASX 200 rallied strongly before giving up about half of its gains towards the close. The index still shows a bullish trend, but resistance just above current levels continues to weigh on momentum. This pattern is not unique to Australia, as many global indices face similar challenges.

The longer-term outlook remains positive, with the ASX 200 holding to its broader uptrend. Even though markets are in what is often considered a “holiday season” with lighter volumes, indices still tend to attract steady inflows during this period. When liquidity improves in the coming weeks, Australia may appeal to both value-seeking investors and momentum traders.

Any pullbacks are expected to find support near the AU$8,800 level, which has become a key area to watch. This suggests that short-term fluctuations may present opportunities for stability within the ongoing trend.

Telstra Group Ltd (TLS)

Telstra Group rose 1.03% as the communication services leader continues to extend its strong performance this year. Over the past 12 months, the stock has gained 24.5% and is now showing signs of consolidation.

The gap left from Thursday’s earnings disappointment is close to being filled, with the top of the gap sitting just below the key AU$5 level. The 50-day EMA has provided support, while trading volume remains solid, lending further weight to the bullish outlook.

RIO Tinto Ltd (RIO)

RIO Tinto fell 1.52% on Monday, with the materials giant showing signs of weak momentum. The stock remains within a broader consolidation range, so a single session does not appear especially significant.

Rising capital expenditures across Australia’s mining industry may be weighing on sentiment, as investors anticipate higher costs. Over the past 12 months, RIO has been largely flat, gaining only 2.92%.

With a dividend of AU$2.276, many view RIO as a longer-term stalwart, but the price action remains range-bound for now. The 50-day EMA sits just below the latest candlestick, while the 200-day EMA rests just above it, reinforcing the sideways outlook.

Sigma Healthcare Ltd (SIG)

Sigma Healthcare gained 0.7% on Monday, extending its impressive 129.27% rise over the past year. Despite that strong run, the stock has been trading flat for several months, consolidating just below the AU$3 mark.

The 200-day EMA sits near AU$2.70, providing a key level of support. With the market moving sideways, the stock appears to be waiting for external catalysts to drive its next move. Recently, Jefferies raised its price target to AU$2.70, which is still below current levels.

At the same time, some analysts have questioned the company’s earnings potential, highlighting a divide in market sentiment. For now, Sigma Healthcare remains remarkably stable, showing little volatility despite differing outlooks.

Disclaimer: The material provided here has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Whilst it is not subject to any prohibition on dealing ahead of the dissemination of investment research we will not seek to take any advantage before providing it to our client. No representation or warranty is given as to the accuracy or completeness of this information and therefore it shouldn’t be relied upon as such. Any research provided does not have regard to specific financial situations, needs or investment objectives. Vantage accepts no responsibility for any use that may be made of these comments and for any consequences that result. Consequently, any person acting on it does so entirely at their own risk. We advise any readers of this material to seek professional advice where necessary. Without the approval of Vantage, reproduction or redistribution of this information isn’t permitted.